breakthrough drugs

By Ben Hirschler LONDON, April 21- New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine on Thursday. Novartis has touted the novel heart failure drug as a $5 billion-a-year seller